ALPN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALPN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alpine Immune Sciences's Enterprise Value is $4,160.78 Mil. Alpine Immune Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-80.96 Mil. Therefore, Alpine Immune Sciences's EV-to-FCF for today is -51.39.
The historical rank and industry rank for Alpine Immune Sciences's EV-to-FCF or its related term are showing as below:
During the past 12 years, the highest EV-to-FCF of Alpine Immune Sciences was 28.49. The lowest was -51.39. And the median was -1.48.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-05), Alpine Immune Sciences's stock price is $64.97. Alpine Immune Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.640. Therefore, Alpine Immune Sciences's PE Ratio for today is At Loss.
The historical data trend for Alpine Immune Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpine Immune Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-FCF | Get a 7-Day Free Trial | -1.31 | 7.41 | -17.93 | -2.59 | -10.47 |
Alpine Immune Sciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-FCF | Get a 7-Day Free Trial | -2.46 | -4.00 | -4.93 | -10.47 | -28.44 |
For the Biotechnology subindustry, Alpine Immune Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Alpine Immune Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Alpine Immune Sciences's EV-to-FCF falls into.
Alpine Immune Sciences's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 4160.775 | / | -80.963 | |
= | -51.39 |
Alpine Immune Sciences's current Enterprise Value is $4,160.78 Mil.
Alpine Immune Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-80.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpine Immune Sciences (NAS:ALPN) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Alpine Immune Sciences's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 64.97 | / | -0.640 | |
= | At Loss |
Alpine Immune Sciences's share price for today is $64.97.
Alpine Immune Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.640.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Alpine Immune Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Mitchell Gold | director, officer: Executive Chairman and CEO | ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102 |
Peter A. Thompson | director | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
James Paul Rickey | officer: Senior VP and CFO | ALPINE IMMUNE SCIENCES, INC., 188 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98102 |
Xiangmin Cui | director, 10 percent owner | NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000 |
Wolfgang Dummer | officer: Chief Medical Officer | 5491 OPTICAL CT., SAN JOSE CA 95138 |
Remy Durand | officer: Chief Business Officer | C/O ALPINE IMMUNE SCIENCES, INC., 185 EAST BLAINE STREET, SUITE 200, SEATTLE WA 98012 |
Jorn Drappa | director | C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878 |
Andrew Seth Sandler | officer: Chief Medical Officer | 1301 2ND AVE, SEATTLE WA 98101 |
Frazier Life Sciences Viii, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Robert E Conway | director | C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021 |
Christopher Peetz | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080 |
Decheng Capital China Life Sciences Usd Fund Iii, L.p. | 10 percent owner | UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104 |
Alpine Immunosciences, L.p. | 10 percent owner | 600 STEWART STREET, SUITE 1503, SEATTLE WA 98101 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Business Wire • 11-03-2023
By Business Wire Business Wire • 11-07-2022
By Business Wire Business Wire • 02-28-2023
By Business Wire Business Wire • 05-11-2023
By GuruFocus Research • 11-15-2023
By Business Wire • 12-18-2023
By Business Wire Business Wire • 03-16-2023
By Business Wire • 11-20-2023
By Business Wire • 11-13-2023
By Business Wire • 09-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.